Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Tracy L. Rose, MD, on Clinical Implications of Treating Bladder Cancer With Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab

Posted: Saturday, March 6, 2021

Tracy L. Rose, MD, of the University of North Carolina at Chapel Hill, discusses phase II study findings supporting the use of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy for patients with muscle-invasive bladder cancer. Dr. Rose offers urologic surgeons and medical oncologists suggestions for coordinating their efforts.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.